ProCE Banner Activity

Key Questions in AL Amyloidosis Care and a Peek Ahead

Clinical Thought

Read this commentary to get expert thoughts on key questions related to diagnosing and managing AL amyloidosis. If you want to learn more, you can register for our live symposium being held at the upcoming ASH 2023 annual meeting.

Released: October 25, 2023

Share

Faculty

Angela Dispenzieri

Angela Dispenzieri, MD

Consultant
Division of Hematology
Serene M. and Frances C. Durling Professor of Medicine and of Laboratory Medicine 
Mayo Clinic
Rochester, Minnesota 

Ashutosh Wechalekar

Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM

Professor of Medicine and Haematology
University College London
Honorary Consultant Haemetologist
University College Hospitals
Director, Jack O’Neil Laboratory
Department of Haematology
National Amyloidosis Centre
London, United Kingdom

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Alexion Pharmaceuticals; Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC; and Prothena Biosciences Limited.

Alexion Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Prothena Biosciences Limited

Disclosure

Primary Author

Angela Dispenzieri, MD

Consultant
Division of Hematology
Serene M. and Frances C. Durling Professor of Medicine and of Laboratory Medicine 
Mayo Clinic
Rochester, Minnesota 

Angela Dispenzieri, MD: researcher: Alexion, Alnylan, Bristol Myers Squibb, Pfizer; consultant/advisor/speaker: Janssen, Sorento.

Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM

Professor of Medicine and Haematology
University College London
Honorary Consultant Haemetologist
University College Hospitals
Director, Jack O’Neil Laboratory
Department of Haematology
National Amyloidosis Centre
London, United Kingdom

Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM: consultant/advisor/speaker: Alexion, Attralus, Janssen, Prothena.